Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 319

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer

Open access
Sethna, Zachary, Guasp, Pablo, Reiche, Charlotte, Milighetti, Martina, Ceglia, Nicholas, Patterson, Erin, Lihm, Jayon, Payne, George, Lyudovyk, Olga, Rojas, Luis A., Pang, Nan, Ohmoto, Akihiro, Amisaki, Masataka, Zebboudj, Abderezak, Odgerel, Zagaa, Bruno, Emmanuel M., Zhang, Siqi Linsey, Cheng, Charlotte, Elhanati, Yuval, Derhovanessian, Evelyna, Manning, Luisa, Müller, Felicitas, Rhee, Ina, Yadav, Mahesh, Merghoub, Taha, Wolchok, Jedd D., Basturk, Olca, Gönen, Mithat, Epstein, Andrew S., Momtaz, Parisa, Park, Wungki, Sugarman, Ryan, Varghese, Anna M., Won, Elizabeth, Desai, Avni, Wei, Alice C., D’Angelica, Michael I., Kingham, T. Peter, Soares, Kevin C., Jarnagin, William R., Drebin, Jeffrey, O’Reilly, Eileen M., Mellman, Ira, Sahin, Ugur, Türeci, Özlem, Greenbaum, Benjamin D., Balachandran, Vinod P.·2025·Nature

Abstract

A fundamental challenge for cancer vaccines is to generate long-lived functional T cells that are specific for tumour antigens. Here we find that mRNA–lipoplex vaccines against somatic mutation-derived neoantigens may solve this challenge in pancreatic ductal adenocarcinoma (PDAC), a lethal cancer with few mutations. At an extended 3.2-year median follow-up from a phase 1 trial of surgery, atezolizumab (PD-L1 inhibitory antibody), autogene cevumeran1 (individualized neoantigen vaccine with backbone-optimized uridine mRNA–lipoplex nanoparticles) and modified (m) FOLFIRINOX (chemotherapy) in patients with PDAC, we find that responders with vaccine-induced T cells (n = 8) have prolonged recurrence-free survival (RFS; median not reached) compared with non-responders without vaccine-induced T cells (n = 8; median RFS 13.4 months; P = 0.007). In responders, autogene cevumeran induces CD8+ T cell clones with an average estimated lifespan of 7.7 years (range 1.5 to roughly 100 years), with approximately 20% of clones having latent multi-decade lifespans that may outlive hosts. Eighty-six percent of clones per patient persist at substantial frequencies approximately 3 years post-vaccination, including clones with high avidity to PDAC neoepitopes. Using PhenoTrack, a novel computational strategy to trace single T cell phenotypes, we uncover that vaccine-induced clones are undetectable in pre-vaccination tissues, and assume a cytotoxic, tissue-resident memory-like T cell state up to three years post-vaccination with preserved neoantigen-specific effector function. Two responders recurred and evidenced fewer vaccine-induced T cells. Furthermore, recurrent PDACs were pruned of vaccine-targeted cancer clones. Thus, in PDAC, autogene cevumeran induces de novo CD8+ T cells with multiyear longevity, substantial magnitude and durable effector functions that may delay PDAC recurrence. Adjuvant mRNA–lipoplex neoantigen vaccines may thus solve a pivotal obstacle for cancer vaccination. In a phase 1 trial, patients with pancreatic ductal adenocarcinoma who were treated with surgery and bespoke neoantigen mRNA vaccines combined with anti-PD-L1 and chemotherapy exhibited marked long-lived persistence of neoantigen-specific CD8+ T cell clones, which correlated with prolonged recurrence-free survival at a 3.2-year follow-up.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-024-08508-4

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 319

Metadata

Authors
Sethna, Z., Guasp, P., Reiche, C., Milighetti, M., Ceglia, N., Patterson, E., Lihm, J., Payne, G., Lyudovyk, O., Rojas, L. A., Pang, N., Ohmoto, A., Amisaki, M., Zebboudj, A., Odgerel, Z., Bruno, E. M., Zhang, S. L., Cheng, C., Elhanati, Y., Derhovanessian, E., Manning, L., Müller, F., Rhee, I., Yadav, M., Merghoub, T., Wolchok, J. D., Basturk, O., Gönen, M., Epstein, A. S., Momtaz, P., Park, W., Sugarman, R., Varghese, A. M., Won, E., Desai, A., Wei, A. C., D’Angelica, M. I., Kingham, T. P., Soares, K. C., Jarnagin, W. R., Drebin, J., O’Reilly, E. M., Mellman, I., Sahin, U., Türeci, Ö., Greenbaum, B. D., & Balachandran, V. P.
Venue
Nature
Published
2025-02-19
Volume
639
Issue
8056
Pages
1042-1051
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4407722177
Cited by
319
References
48
FWCI
95.09
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. https://app.cochat.ai/papers/10.1038/s41586-024-08508-4
The paper
Sethna, Z., Guasp, P., Reiche, C., Milighetti, M., Ceglia, N., Patterson, E., Lihm, J., Payne, G., Lyudovyk, O., Rojas, L. A., Pang, N., Ohmoto, A., Amisaki, M., Zebboudj, A., Odgerel, Z., Bruno, E. M., Zhang, S. L., Cheng, C., Elhanati, Y., . . . Balachandran, V. P. (2025). RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature. https://doi.org/10.1038/s41586-024-08508-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.